NIKKEI 225
27,346.88 +19.77 (+0.07%) HANG SENG
22,072.18 +229.85 (+1.05%) CRUDE OIL
76.86 +0.45 (+0.59%) GOLD FUTURES
1,968.90 +26.10 (+1.34%) DOW
34,092.96 +6.92 (+0.02%) BTC-GBP
19,174.79 +427.79 (+2.28%)
Celyad SA (CYAD)
After hours:
| Previous close | 1.3500 |
| Open | 1.3400 |
| Bid | 1.3100 x 1000 |
| Ask | 1.5000 x 1100 |
| Day's range | 1.2500 - 1.4204 |
| 52-week range | 0.4600 - 3.6300 |
| Volume | |
| Avg. volume | 1,516,656 |
| Market cap | 30.694M |
| Beta (5Y monthly) | 1.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4880 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.29 |
- Business Wire
Celyad Oncology Provides an Update on Its Strategic Business Model, Continuing to Focus on Opportunities to Fully Harness the True Potential of Its Proprietary Technology Platforms and Intellectual Property
MONT-SAINT-GUIBERT, Belgium, December 21, 2022--Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (the "Company") (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today provides an update on its Celyad 2.0 business strategy which has been adopted and implemented over the last few months.
- Business Wire
Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights
MONT-SAINT-GUIBERT, Belgium, November 10, 2022--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company"), a biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today provided an update on its financial results and recent business developments for the fiscal quarter ended September 30, 2022.
- Business Wire
Celyad Oncology Provides Strategic Update
MONT-SAINT-GUIBERT, Belgium, October 12, 2022--Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD), a biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today provided an update on its strategic business model, clinical trial programs, and the related operational and organizational steps and cost-saving measures that it will undertake.
